Zika Virus infection and Microcephaly: some Doctors suspect Pesticides

Report from Physicians in the Crop-Sprayed Villages regarding Dengue-Zika, microcephaly, and mass-spraying with chemical poisons

image of child-and-polluted-river
Argentine and Brazilian doctors dismiss the Zika virus in causing severe cranial malformations in newborns in Brazil. And involve the use of an insecticide produced by Monsanto’s partner supposed to protect dengue.

Report Main points:

Experts debunk claim blaming larvicide, not Zika, for microcephaly, cbsnews, February 16.

  • Dengue epidemic in Brazil persists endemically (on an ongoing basis) due to the marginalisation and misery of millions of people, especially in Northeast Brazil. On top of that, Zika virus, a similar disease although more benign, is now spreading.
  • A dramatic increase of congenital malformations, especially microcephaly in newborns, was detected and quickly linked to the Zika virus by the Brazilian Ministry of Health. However, they fail to recognise that in the area where most sick persons live, a chemical larvicide producing malformations in mosquitoes has been applied for 18 months, and that this poison (pyroproxyfen) is applied by the State on drinking water used by the affected population.
  • Previous Zika epidemics did not cause birth defects in newborns, despite infecting 75% of the population in those countries. Also, in other countries such as Colombia there are no records of microcephaly; however, there are plenty of Zika cases.
  • The pyroproxyfen being used (as recommended by WHO) is manufactured by Sumimoto Chemical, a Japanese subsidiary of Monsanto.
  • Brazilian doctors (Abrasco) are claiming that the strategy of chemical control is contaminating the environment as well as people, that it is not decreasing the amount of mosquitoes, and that this strategy is in fact a commercial manoeuvre from the chemical poisons industry, deeply integrated into Latin American ministries of health as well as WHO and PAHO.
  • Massive spreading using planes, as the governments of Mercosur are considering, is criminal, useless, and a political manoeuvre to simulate that actions are taken. The basis of the progress of the disease lies in inequality and poverty, and the best defence are community-based actions.
  • The last strategy deployed in Brazil, and which might be replicated in all our countries, is the use of GM mosquitoes —a total failure, except for the company supplying mosquitoes.

Click to download the whole report.

Baby cosmetics still contain too many ingredients of concern

WECF releases survey on 341 baby cosmetics products of which 299 contain high risk ingredients

Safety of Cosmetic Products for Babies Called Into Question by WECF France
Safety of Cosmetic Products for Babies Called Into Question by WECF France.

Using analysis of existing scientific literature and opinions from European Union and French risk assessment agencies, experts classified ingredients or groups of ingredients into three categories: high risk, moderate risk and low or not identified risk.

WECF found that three ingredients or ingredient families it considered high risk are in 299 of the products. These include methylisothiazolinone, a contact allergen; perfume or fragrance, which may involve potential allergy risks, and phenoxyethanol, a preservative suspected to be reprotoxic.

There are also four ingredients or ingredient families that were classified as moderate risk found in 181 products. They are: EDTA, commonly used in foaming products; laureth and lauryl sulfate, which are foaming agents; mineral oils, byproducts of petroleum, which could be contaminated by impurities, and nanoparticles.

More information
  • Safety of Cosmetic Products for Babies Called Into Question by WECF France, wecf, 16.02.2016.
  • Baby cosmetics still contain too many ingredients of concern, wecf, 15.02.2016.
  • RAPPORT Cosmétiques pour bébés, wecf, 16.02.2016.
  • Rapport cosmétiques FINAL, Wecf, 15.02.2016.

What are Clinical Trial Phases?

Watch this whiteboard animation to learn about the three main phases of clinical trials

Clinical trials are research studies that involve people. Understanding what they are can help you decide if a clinical trial might be an option for you or a loved one.

More info and videos

Are you Too Young for a Pap Test? Become aware of the Cervical Cancer Symptoms

Heather – now cance-free – was diagnosed with cervical cancer a year before she became eligible for smear tests… she shares her tips

image of too-young-for-pap-test
Heather wants to share her story so that there is more awareness around cervical cancer.

I want to share my story, to help others be more aware of the symptoms of cervical cancer. So that girls under 25 that are not entitled to a free smear know what to look out for and for those who are over 25 be more aware of the importance of going for your smear.

Symptoms

  • Abnormal bleeding
    • heavy or longer periods
    • between periods
    • after sex
    • after menopause
  • Foul smelling discharge
  • Pain or discomfort in the pelvis or during sex

Sources

Diethylstilbestrol Studies with Ethical Violations

Research ethics: where do you draw the line?

1950’s illegal studies that violated the Hippocratic Oath, the Nuremberg Code, and the Declaration of Helsinki.

Sources:
More DES DiEthylStilbestrol Resources

Better understanding of the risks of valproate medicines and pregnancy

New toolkit by The Medicines and Healthcare products Regulatory Agency (MHRA)

A toolkit to ensure female patients are better informed about the risks of taking valproate medicines during pregnancy has been launched.

The Medicines and Healthcare products Regulatory Agency (MHRA) today welcomed the launch of a new toolkit to ensure female patients are better informed about the risks of taking valproate medicines during pregnancy.

Valproate (Epilim, Depakote and other generic brands) is a treatment for epilepsy and bipolar disorder and is prescribed to thousands of women. It is associated with a risk of birth defects and developmental disorders in children born to women who take valproate during pregnancy.

MHRA strengthened warnings on the risks of valproate in pregnancy last year, as understanding of the extent of these risks had increased. Up to 4 in 10 babies are at risk of developmental disorders, and approximately 1 in 10 are at risk of birth defects, if valproate is taken during pregnancy. The new toolkit addresses concerns that the risks of valproate are not being adequately explained to female patients.

Developed in consultation with stakeholders including healthcare professional and patient groups, the toolkit includes a credit card sized patient card to be issued by pharmacists, booklets for healthcare professionals and for patients together with a checklist of important questions and discussion points to be kept with the patient’s file. Warnings will appear on the medicine’s packaging later this year.

The MHRA is asking GPs, pharmacists, neurologists, psychiatrists, and other relevant healthcare and mental health professionals to use the toolkit to help facilitate discussion of the risks with their patients.

Sources and more information
  • New toolkit supports better understanding of the risks of valproate and pregnancy, GOV.UK Press release, 8 February 2016.
  • Toolkit on the risks of valproate medicines in female patients, GOV.UK Guidance, 8 February 2016.

Global impact of antibiotic resistance

TARGET stands for: Treat Antibiotics Responsibly, Guidance, Education, Tools

image of Global-impact-of-antibiotic
TARGET stands for: Treat Antibiotics Responsibly, Guidance, Education, Tools.

The TARGET Antibiotics Toolkit aims to help influence prescribers’ and patients’ personal attitudes, social norms and perceived barriers to optimal antibiotic prescribing. It includes a range of resources that can each be used to support prescribers’ and patients’ responsible antibiotic use, helping to fulfil CPD and revalidation requirements.

Health posters
Related posts

Antibiotic discovery and resistance timeline

TARGET stands for: Treat Antibiotics Responsibly, Guidance, Education, Tools

image of Antibiotic-timeline
TARGET stands for: Treat Antibiotics Responsibly, Guidance, Education, Tools.

The TARGET Antibiotics Toolkit aims to help influence prescribers’ and patients’ personal attitudes, social norms and perceived barriers to optimal antibiotic prescribing. It includes a range of resources that can each be used to support prescribers’ and patients’ responsible antibiotic use, helping to fulfil CPD and revalidation requirements.

Health posters
Related posts

Significant medical data

How some scientists – and news – can play with medical data…

How Scientists Are Doing A Bait-And-Switch With Medical Data

A scientific result is considered “statistically significant” if there’s a less than one in 20 chance that it could happen by chance – if you measure 20 different things, you’ll probably get one positive result, as this XKCD demonstrates.

Sources
  • Image: Significant, xkcd webcomic of romance, sarcasm, math, and language.
  • How Scientists Are Doing A Bait-And-Switch With Medical Data, BuzzFeed, Jan. 22, 2016.
  • Enjoy our health comic strips album on Flickr.
Related

Distilbène dragées bleues et roses par UCB pharma

Archives Institut National de l’Audiovisuel Ina Sciences, 1983

image de distilbene-dragées
Ces dragées bleues et roses de distilbène 1 et 5 mg étaient produites par UCB pharma.

Le Diethylstilbestrol ou DES a été commercialisé via de nombreux noms tels que le Distilbène®, Stilbetin®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® et Estrosyn® par exemple.

Nombre de sociétés ont promu et vendu leur médicament DES sous plus de 200 noms de marque différents.

Ces dragées bleues et roses de distilbène 1 mg et 5 mg étaient produites par UCB pharma.

Images de médicaments DES
Le Distilbène DES, en savoir plus